Clin Nucl Med. 2018 Apr;43(4):232-238. doi: 10.1097/RLU.0000000000001984.
Planar whole-body imaging with I-radiolabeled metaiodobenzylguanidine (I-MIBG) is routinely used in the follow-up evaluation of neuroblastoma. In recent years, SPECT with integrated low-dose CT (SPECT/CT) has become more accessible. We investigated how much SPECT/CT can have additional diagnostic value over planar imaging in detection of residual and recurrent neuroblastoma.
A total of 170 planar I-MIBG imaging scans with SPECT/CT follow-up scans performed in 147 patients with known high-risk neuroblastoma were retrospectively analyzed. Regions of increased I-MIBG uptake on planar images and the findings on SPECT/CT were compared.
In 61% of the studies, the whole-body planar images and SPECT/CT images yielded the same result. In 39% of the time, however, SPECT/CT images provided additional information.
In the follow-up of patients with high-risk neuroblastoma, SPECT/CT can significantly improve planar imaging interpretation and impact patient management.
放射性碘标记间碘苄胍（I-MIBG）平面全身成像已常规用于神经母细胞瘤的随访评估。近年来，集成低剂量 CT 的 SPECT（SPECT/CT）已更普及。我们研究了 SPECT/CT 相对于平面成像在检测残留和复发性神经母细胞瘤方面能提供多少额外的诊断价值。
回顾性分析了 147 例已知高危神经母细胞瘤患者的 170 次平面 I-MIBG 成像扫描和 SPECT/CT 随访扫描。比较了平面图像上 I-MIBG 摄取增加的区域和 SPECT/CT 的发现。
在 61%的研究中，全身平面图像和 SPECT/CT 图像得出了相同的结果。然而，在 39%的时间里，SPECT/CT 图像提供了额外的信息。
在高危神经母细胞瘤患者的随访中，SPECT/CT 可以显著改善平面成像的解读，并影响患者的管理。
